...when it comes to disappointment vs. Merck - whether it is Capoten vs. Vesotec; Pravachol vs. Zocor; or Opdivo vs. Keytruda. The BMS executives are either too arrogant, or too stupid - perhaps both!
$40Bn wiped off the market cap, class action ongoing, 227 was PROVE-IT all over again. Insiders driven by LTIs only. Bio markers were not allowed to be discussed a couple of years back as it was seen as “not thinking big enough” Coke/Pepsi analogy? WTF.....Lynelle spins, Murdo thinks Adam is the “son he never had” and Johanna is so old her admin needs to be a registered nurse. But at the end of the day my golf handicap is awesome, 6 of us discussing our customers gives us all enough bullshit to stay ahead of management.
BMS beat the earnings, and the sock is down. This management has become the Rodney Dangerfield of the drug industry - no offense to Rodney.
Hepatitis C drugs Viekira and Mavyret "crushed it," Raymond said in a report to clients. Together, they brought in $919 million, nearly doubling consensus views for $523 million. Sales outside the U.S. were $576 million, beating views for $276 million.
Bristol-Myers Squibb has pulled two phase 3 clinical trials of the IDO1 inhibitor it acquired through an $800 million takeover of Flexus.......
Explains the $1 billion in org cuts. They’ll make that right back using employees as clawback profit centers limiting cell phone/fax/mobile data/business internet reimbursements to $100, jack insurance premiums for a self-insured company and raise prices in the cafeteria.
Ummm what $1 billion in org cuts? They hiring like crazy in the Lawrenceville office. So much so they are running out of space and practically every CUBE has two people in it.
